Artelo Biosciences (NASDAQ:ARTL) Given Buy Rating at HC Wainwright

Artelo Biosciences (NASDAQ:ARTL)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $5.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 327.35% from the stock’s current price.

Separately, EF Hutton Acquisition Co. I upgraded Artelo Biosciences to a “strong-buy” rating in a research report on Tuesday, October 1st.

Artelo Biosciences Trading Down 5.4 %

Shares of Artelo Biosciences stock opened at $1.17 on Wednesday. The firm has a market capitalization of $3.78 million, a PE ratio of -0.35 and a beta of 1.35. The business’s 50-day moving average price is $1.16 and its 200-day moving average price is $1.28. Artelo Biosciences has a 12 month low of $1.00 and a 12 month high of $1.75.

Artelo Biosciences (NASDAQ:ARTL) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.10. As a group, analysts predict that Artelo Biosciences will post -2.41 earnings per share for the current fiscal year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.